ALK and non-small cell lung carcinoma: Herein, alectinib- or brigatinib-DT cells from mesenchymal-like ALK-rearranged NSCLC exhibited MET with increased E-cadherin expression and reduced mesenchymal marker (ZEB1 and vimentin) expression, but reverted to a mesenchymal phenotype following HER3 inhibition or ZEB1 overexpression.